Mentors


Meet the mentors of the of the Henri Termeer Network. To inquire about becoming a mentor, This email address is being protected from spambots. You need JavaScript enabled to view it..

Jeff Albers

Jeff Albers


Jeff Albers is the CEO, President and Member of the Board of Directors at Blueprint Medicines in Cambridge, MA. He also currently serves on the Board of Directors of Magenta Therapeutics, Kymera Therapeutics, the New England American Cancer Society, and is on the board of advisors of Life Science Cares. Jeff has more than 25 years of experience working in the biopharmaceutical industry and bringing important new medicines to patients with cancer and rare diseases.

In 2014, he joined Blueprint Medicines as Chief Executive Officer and led the research-stage company through an initial public offering. Since that time, Blueprint Medicines has evolved into a leading precision medicine company with a global, fully integrated business, including one FDA-approved therapy and a rapidly advancing pipeline.

Jeff previously served as President of Algeta, where he oversaw the successful commercial launch of a targeted cancer therapy prior to the company’s acquisition by Bayer. Prior to Algeta, Jeff held senior commercial and corporate development positions at Genzyme (now a division of Sanofi), most recently as vice president of the U.S. hematology and oncology business unit. After several years in Corporate Development roles at Genzyme, Jeff was called to Henri’s office to meet with Henri and Peter Wirth, where they unexpectedly offered him a position as the head of the U.S. transplant business. Jeff views this moment as a critical inflection point in his career as these two mentors were clearly willing to “take a chance” on him and place him in a role that would expand and accelerate his career growth. Earlier in his career, Jeff was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo.

Jeff holds a B.S. from Indiana University and an MBA and J.D. from Georgetown University.

Areas of Expertise: Financing/IR; company building – recruiting/talent; Commercial build; Partnering / BD.


Mike Bonney

Mike Bonney


Mike Bonney is a business executive with over 30 years of biotech and pharmaceutical expertise. Bonney was CEO and Director of Cubist Pharmaceuticals from 2003 until 2014. Under his leadership, Cubist grew from a struggling micro-cap to the world’s leading antibiotic company and was acquired by Merck early in 2015 for $9.5 billion. Prior to Cubist, Bonney was Vice President of Sales and Marketing at Biogen where he built the company’s commercial infrastructure for the launch of its first product. Before joining Biogen, he spent 11 years at Zeneca Pharmaceuticals in a range of commercial, operating, and strategic roles, ending his career there as National Business Director.

Bonney chairs the boards of Alnylam Pharmaceuticals, Kaleido Biosciences and Magenta Therapeutics. He is a member of several other boards, including Bristol Myers Squibb. Bonney spends much of his time identifying and mentoring the next generation of life science leaders.

Bonney was a regional winner and national finalist (2013) in the life science segment of Ernst & Young’s Entrepreneur of the Year and was one of six executives nationwide named as Marketwatch’s CEO of the Year (2011). He received his undergraduate degree in economics from Bates College.

Mike and his family have a wide range of philanthropic interests including education – Mike chaired the Board of Bates College from 2010 – 2019; the Gulf of Maine Research Institute, where the Bonney’s focus is on sustainable economic activity in the rapidly changing Gulf of Maine, with a specific focus on shellfish and seaweed aquaculture; and Rare, an international NGO focused on inspiring change, so people and nature thrive.

Areas of expertise: Company, team and board building; executive and leadership development; succession planning; corporate and non-profit governance; capital raising; strategic planning.


John Butler

John Butler


John Butler joined Akebia as President and CEO in September, 2013. He has more than 25 years of experience leading the development, launch and commercialization of innovative therapies. He served as CEO of Inspiration Biopharmaceuticals, a company focused on developing products for patients with hemophilia, from 2011 until 2013. He led the sale of the company’s assets, including the company’s lead asset to Baxter Corporation, the world leader in hemophilia. The value of the transactions should total over $1 billion to Inspiration’s shareholders.

From 1997 to 2011, John held various positions at Genzyme. While at Genzyme, he most recently served as President of the company’s rare genetic diseases business, which has developed and commercialized first-to-market, transformative therapies for small patient populations. John also led the company’s renal, endocrinology, and cardiovascular businesses, growing the division to $1 billion in revenue. Earlier in his career, he held sales and marketing positions at Amgen and Hoffmann-La Roche.

He has spent over twenty years working to improve the lives of patients with kidney disease. He served in a number of commercial roles while at Amgen for Epogen® and he led the renal business at Genzyme which brought Renagel®, Renvela®, and Hectorol® to these patients. He was a member of the board of directors of Relypsa, Inc. a company developing a first in class treatment for hyperkalemia in patients with CKD, and served as Chairman of the Board at Keryx Biopharmaceuticals, a commercial stage company developing innovative products for people with renal disease. Additionally, he served as the chairman of the American Kidney Fund board of trustees from 2013-2015. The AKF is the leading patient focused charitable organization in kidney disease providing assistance to one in 5 patients on kidney dialysis in the US.

John received his BA degree in Chemistry from Manhattan College and his MBA degree from Baruch College.

Areas of Expertise: commercial strategy, business development, alliance management, and company building.


Daniel De Boer

Daniel De Boer


Daniel De Boer is Founder and Chief Executive Officer of ProQR Therapeutics. After one of his children was diagnosed with a rare disease, he started ProQR to develop RNA therapies for rare diseases. Under Daniel’s leadership ProQR developed a platform that yielded a diversified pipeline of potential treatments for rare diseases, and raised approximately $400M in funding, including an IPO on Nasdaq. Before founding ProQR, Daniel was founder and Chief Executive Officer of several technology companies. Daniel is also co-founder and strategic advisor to Amylon Therapeutics and Wings Therapeutics, strategic advisor at Frame Therapeutics, Meatable and Algramo, and a member of the board of advisors at The Termeer Foundation. In 2018 Daniel was named "Emerging Entrepreneur of the Year" by EY. In 2019 Daniel was selected for the Young Global Leader program at the World Economic Forum.

Daniel met Henri in late 2011, after stalking him for months to get a meeting. Six months later they co-founded ProQR Therapeutics. Daniel had the privilege of working closely with Henri as a board member in the years after and benefit from his mentorship in building ProQR.

Areas of Expertise: Company initiation and building; Fundraising private and public, including IPO; Building patient-centric organization.


Eli de los Pinos

Eli de los Pinos


Eli de los Pinos is the founding CEO of Aura, which she created from the ground up: She developed the company concept collaborating with Lasker award winner Dr. John Schiller at the National Cancer Institute and spearheaded fundraising efforts, raising a total of $140M in multiple rounds of financing. Prior to founding Aura, she worked in Eli Lilly & Co.’s oncology business unit, where she was part of the leadership team responsible for the market launch in Europe of Alimta, a drug for the treatment of lung cancer. Earlier in her career, Eli worked as a post-doctoral fellow at the Institute of Cancer Research in London. She previously completed fellowships at the Mount Sinai School of Medicine Institute of Molecular Medicine and at the Georgetown School of Medicine. Eli holds a Ph.D., magna cum laude, in Molecular Biology from the University of Barcelona and an MBA from IE Business School.

She is a member of the board of overseers at the Museum of Science, Boston. Eli has also been named to Boston Business Journal's “Top 40 under 40” list; as a Mass High Tech “Woman to Watch”; as a “Technology Pioneer” by the World Economic Forum; and as one of Goldman Sachs’ “100 Most Intriguing Entrepreneurs”.

Eli first met Henri in 2010 right after moving to Boston from Spain to start Aura. As a first time female CEO, Eli was privileged to have Henri’s mentorship in those early and challenging years guiding her to define the company’s strategy and Board of Directors, actively participating in her seed round of angel investors and in every financing round thereafter, introducing her to his closest business network and later becoming a Board member and key strategic advisor.

Areas of Expertise: Fundraising: Angel/Family Office and Venture Capital; Company Creation; General Management; Business Strategy; Research and Development: Rare Diseases, Oncology & Ophthalmology


Roch Doliveux

Roch Doliveux


Roch Doliveux is currently Chairman of the Board of Directors for Pierre Fabre Group and Oxford Biomedica, as well as Chairman of the GLG Healthcare Institute. He is also a member of the board of directors at UCB and Stryker Corp. He also chairs the Caring Entrepreneurship Fund, a philanthropic initiative which he created in 2008 and which supports entrepreneurship in health and wellness.

Roch previously served as CEO at UCB, a position he held for more than a decade. Under his CEO tenure at UCB, Doliveux transformed the company from a diversified chemical group to a focused global biopharmaceutical leader. Prior to joining UCB, he held positions at Schering-Plough Corp., including President of Schering-Plough International, and at Ciba-Geigy (now Novartis).

Roch has a Doctor in Veterinarian Medicine from Maisons-Alfort (France), and he is Laureate of the Faculty of Medicine, Créteil, and holds an MBA with distinction from INSEAD (France). Doliveux was awarded the Doctor Honoris Causa degree of the University of Liège (Belgium) in and was bestowed the title of Commander of the Order of the Crown by the Belgian government.

Areas of Expertise: - experienced global biopharma CEO over 10 years - Experienced chairman of Boards over 4 years - Maximising potential of talents and teams - Interface between science and business - Company transformation and M&A


Mark Enyedy

Mark Enyedy


Mark Enyedy joined ImmunoGen in 2016 as President and Chief Executive Officer, bringing over twenty-five years of combined general management, business development and legal experience in the biotechnology industry. He joined ImmunoGen from Shire plc, where he served as Executive Vice President and Head of Corporate Development, leading the company’s Strategy, M&A, and Corporate Planning functions and providing commercial oversight for the company’s pre-Phase 3 portfolio.

Previously, Mark served as CEO of Proteostasis Therapeutics, Inc., following 15 years at Genzyme Corporation in diverse roles, most recently as President of the Transplant, Oncology, and Multiple Sclerosis divisions. Before joining Genzyme, Mark was an associate with the Boston law firm Palmer & Dodge.

Mark serves on the Board of Directors of Akebia Therapeutics, Inc. and The American Cancer Society of Eastern New England.

Mark holds a J.D. from Harvard Law School and a B.S. from Northeastern University.

Areas of Expertise: M&A; Oncology Development Commercialization; Corporate Strategy; Transformation.


Alison Lawton

Alison Lawton


Alison Lawton is currently Special Advisor to the Office of the CEO of Kaleido Biosciences, where she was previously President and CEO for two years and President & COO for one year. Alison has served as Chief Operating Officer of Aura Biosciences and OvaScience and served as a biotech consultant for various companies, including as Chief Operating Officer for X4 Pharmaceuticals (XFOR). Prior to that, Alison spent more than 20 years in various positions of increasing responsibility at Genzyme Corporation, and subsequently at Sanofi-Aventis, following its acquisition of Genzyme, including as General Manager & Senior Vice President of Genzyme Biosurgery, a $800M revenue business which included orthopedics, surgical and cell therapy & regenerative medicines.

Previously she was Senior VP Global Market Access which included Regulatory Affairs, Health Outcomes & Strategic Pricing and Public Policy. Before joining Genzyme, Alison was based in the UK with Parke-Davis, a pharmaceutical company.

Alison currently serves as a member of the board of directors of ProQR Therapeutics N.V. (PRQR), Aeglea Biotherapeutics (AGLE), X4 Pharmaceuticals (XFOR) and Magenta Therapeutics Inc. (MGTA). She previously served on the board of Kaleido Biosciences (KLDO), Verastem, Inc. (VSTM), CoLucid Pharmaceuticals, Inc. (CLCD) until its acquisition by Eli Lilly and Cubist Pharmaceuticals (CBST) until its acquisition by Merck &Co. She is past President and Chair of the Board of Regulatory Affairs Professional Society and past FDA Advisory Committee member for Cell and Gene Therapy Committee.

Areas of expertise: Regulatory strategy, product and clinical development, company building including international, and fund-raising including IPO.


John Maraganore

John Maraganore


John Maraganore has served as the CEO and a Director of Alnylam since 2002.

Prior to Alnylam, John served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. As Senior Vice President, Strategic Product Development for Millennium, he was responsible for the company’s product franchises in oncology, and cardiovascular, inflammatory, and metabolic diseases. He was previously Vice President, Strategic Planning and M&A and, prior to that, he was General Manager of Millennium BioTherapeutics, Inc., a former subsidiary of Millennium. Before Millennium he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. At Biogen, John invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection, formerly HIRULOG™ and currently marketed by The Medicines Company. Prior to Biogen, John was a scientist at ZymoGenetics, Inc., and the Upjohn Company.

John is the Chair of the Board for Agios Pharmaceuticals, former Chair of the Biotechnology Innovation Organization (BIO) Board, a member of the BIO Executive Committee, and co-chair of the Termeer Tribute Committee.

John received his MS and PhD in biochemistry and molecular biology at the University of Chicago.

Areas of Expertise: General Management; Leadership and Strategy; Science and Clinical Development; and Communications.


Thomas P. Mathers

Thomas P. Mathers


Tom P. Mathers is the Founder, President and CEO of Allievex, a biotechnology company focused on the development of novel therapeutics for the treatment of rare pediatric neurodegenerative diseases. He is also a partner at Pappas Capital, a dedicated life science venture capital firm focused exclusively on investing in the life sciences sector across the United States and Canada.

Prior to Pappas Capital and Allievex, Tom was the President and CEO of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD), which focused on the development of lasmiditan (Reyvow™) for the acute treatment of migraine headaches. Eli Lilly & Company acquired CoLucid in March 2017 in an all cash transaction for $1 billion. Prior to CoLucid, Mr. Mathers was President and CEO of Peptimmune, Inc.; President and CEO of Cell Based Delivery, Inc; Vice President and General Manager of Cardion AG; and Vice President of Strategic Development at Genzyme Corporation.

Tom is also currently serving as a Trustee of Butler University, 4D Molecular Therapeutics, and as co-founder and Chairman of Déclion Holdings, a biopharmaceutical company focused on the discovery and development of innovative treatments for neurodegenerative diseases. He has previously served on the Board of Directors for the Biotechnology Industry Organization for nine years, where he was active in the policy areas of capital formation, bioethics, intellectual property, and regulatory policy.

Tom earned a BS in Engineering from the United States Military Academy at West Point in 1988, where he also played football for four years. He went on to serve as a Captain in the United States Army and received several medals for his service as an AH-64 Apache helicopter pilot during the Gulf War.

Areas of Expertise: Company founding and building, R&D and pipeline strategy, partnering and business development, venture capital and fundraising, and general management.


Geoff McDonough

Geoff McDonough


Geoff McDonough is the President & Chief Executive Officer of Generation Bio. Geoff formerly served as president and chief executive officer of Swedish Orphan Biovitrum AB (Sobi) from 2011 – 2017. Prior to Sobi, he held a variety of senior roles at Genzyme Corporation, including president of Genzyme Europe and senior vice president and general manager of the global lysosomal storage disease business.

Geoff has a Bachelor of Science in biology and a Bachelor of Arts in philosophy from University of North Carolina at Chapel Hill, graduating summa cum laude in both. He obtained his doctor of medicine at Harvard Medical School and completed his residency training in internal medicine and pediatrics at Massachusetts General Hospital and Boston Children’s Hospital.

Areas of Expertise: rare disease
- company building - leadership and development - global commercialization - regulatory engagement - private and public fundraising - investor relations - patient voice


David Meeker

David Meeker


David Meeker is the Chairman, President & CEO of Rhythm Therapeutics, a biotechnology company focused on developing innovative therapies for rare genetic disorders of obesity. Dr. Meeker was formerly the President and CEO of Genzyme, a Sanofi company, a position he assumed when Genzyme merged with Sanofi in 2011. He was also a member of the Sanofi executive committee. He was most recently CEO of KSQ Therapeutics an early stage functional genomics company.

In his career with Genzyme, David held key positions of increasing responsibility beginning in the R&D organization and subsequently in operating roles, culminating in the position of Chief Operating Officer at the time of the merger. In his most recent role within Sanofi, he headed Sanofi-Genzyme, the specialty care unit with responsibility for Rare Diseases, MS, Oncology and Immunology franchises. Prior to joining Genzyme, David was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He completed his internal medicine training at Harvard’s Beth Israel Hospital and his pulmonary/critical care training at Boston University. He completed the Advanced Management Program at Harvard Business School in 2000.

David is the Chairman of the Board of Trevi Therapeutics and a member of the board at Myokardia. He also serves on the boards of the Biomedical Science Careers Program, the Network for Excellence in Health Innovation and the Dimock Center, a Boston based community health center.

Areas of Expertise: Leadership and corporate strategy; governance and board building; clinical development strategy; rare disease community building; Global expansion; business development.


Paula Ragan

Paula Ragan


Paula Ragan has more than 20 years of experience building and leading companies in the biotechnology industry. Since 2014, Dr. Ragan has been the Chief Executive Officer and a member of the Board of Directors of X4 Pharmaceuticals in Cambridge, MA.

Previously, Paula consulted as Chief Business Officer at Lysosomal Therapeutics Inc. (LTI), an Atlas Venture portfolio company, where she led the company’s business activities. From 2007-2012, Paula held leadership roles in corporate development and operations at Genzyme/Sanofi where she led strategic partnering efforts for Genzyme’s Rare Disease business and headed the supply chain planning for Genzyme’s flagship commercial products. Other professional roles include business roles at Hydra Biosciences, Oscient Corporation and Celera Corporation.

Paula received her PhD in Medical Engineering and Medical Physics from MIT and completed post-doctoral studies at Harvard Medical School.

Areas of Expertise: Start-up do’s and don’ts, Business/corporate development, Financing strategy, Corporate culture


Alicia Secor

Alicia Secor


Alicia Secor is an accomplished 25+ year healthcare executive with a demonstrated track record in leading teams from product development through regulatory approval, and commercialization across multiple therapeutic areas spanning orphan and prevalent diseases.

Alicia is currently President & CEO (and member of BOD) of Atalanta Therapeutics, a privately held company focused on neurodegeneration. She also recently served as president and chief executive officer at Juniper Pharmaceuticals, Inc., a diversified public healthcare company where she led the successful turnaround strategy for the company resulting in a sale to Catalent, Inc. in August 2018.

Prior to her role at Juniper, Alicia held a number of leadership positions in the life sciences industry, including chief commercial officer at Zafgen Inc., senior vice president and chief operating officer at Synageva BioPharma Corp, and roles of increasing responsibility at Genzyme over her 15-year tenure, including serving as vice president and general manager of metabolic diseases, a global business with multiple commercial products, including two orphan drugs. Prior to Genzyme, Secor held positions at Alkermes, Inc. in business development, at Centocor, Inc. (a Johnson & Johnson Company) in clinical and commercial operations, and began her career at Pfizer Inc. as a hospital-based sales representative.

Alicia is also a member of the board of directors at GW Pharmaceuticals, plc., Orchard Therapeutics, and a board member of the Foundation for Prader-Willi Research (FPWR).

She received her B.S. in health administration from the University of New Hampshire and an MBA from Northeastern University.

Areas of Expertise: Commercial: from pre-launch prep to post-launch life-cycle management; Investor relations (C-Suite perspectives); Patient advocacy; Corporate culture development; Crisis leadership (navigating teams and businesses through ups, downs, and turnarounds).


Paula Soteropoulos

Paula Soteropoulos


Paula Soteropoulos is the Executive Chairman of the Board of a NewCo seeded by 5AM Ventures. She also is as a Strategic Advisor to 5AM Ventures and is a member of the Supervisory Board of Directors of gene therapy leader, uniQure. Paula has more than 30 years of experience in the biopharma industry in areas of drug development, manufacturing, business development, global commercialization with P&L accountability, company building and organizational development.

Prior, she served as the CEO and a member of the board of directors of rare disease therapeutic developer Akcea Therapeutics. Paula was the founding President and CEO in 2015 and led the company through its IPO on NASDAQ in 2017, as well as significant growth: employing over 270 staff in thirteen countries, six drugs in its portfolio with 2 rare disease drug approvals and commercial launches. Previously, she served as Senior Vice President and General Manager, Cardiometabolic and Rare Disease Businesses & Strategic Alliances at Moderna Therapeutics and worked for over 20 years at Genzyme Corporation, most recently as Vice President and General Manager, Cardiovascular, Rare Diseases. She credits Henri and other Genzyme mentors for their willingness to take risks on her, giving her growth opportunities in varied roles from engineering and manufacturing to leading global commercial businesses.

Paula earned her B.S. and Master’s degrees in Chemical and Biochemical Engineering from Tufts University and earned an executive management certificate from Darden School of Business, University of Virginia. She also serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University.

Areas of Expertise: Company and culture building; New ventures; IPO and Investor relations; Rare disease development and commercialization; Global expansion; Strategic collaborations; Building a board & governance; Diversity/Female mentorship


Alan Walts

Alan Walts


Alan Walts co-founded The Termeer Foundation and serves as its Treasurer, Secretary, and as a director. He also serves as Executive Chairman of PIC Therapeutics, Artax Biopharma and Ziknani Therapeutics. Alan is a Board Observer for Aura Biosciences, Amylyx Pharmaceuticals and Arrakis Therapeutics. He is also a US-based Venture Partner with Advent Life Sciences and on the Advisory Board of the ALS Investment Fund.

Alan was a Business Advisor to Henri Termeer from 2013 - 2017, and worked closely with Henri on founding and investing in early stage companies. He first met Henri in 1983 at Genzyme and had the remarkable good fortune to learn from Henri throughout his career at Genzyme. While demanding excellence, Henri provided regular advice, guidance, and mentoring during Walts’s career at Genzyme and thereafter. Alan has over 25 years of industry experience at Genzyme in business development, business strategy, research and development, general management, and venture capital. Prior to leaving Genzyme in 2013, he most recently managed Genzyme’s corporate venture fund, Genzyme Ventures (now Sanofi Ventures).

Alan received a Ph.D. in chemistry from MIT in 1985, carried out post-doctoral research in biochemistry at MIT with Professor Christopher Walsh, and completed the executive Program for Management Development at Harvard Business School.

Areas of Expertise: Company founding and building, R&D and pipeline strategy, partering and business development, venture capital and fundraising, and general management.


Peter Wirth

Peter Wirth


Peter Wirth is a Venture Partner with Quan Capital Management, a global life sciences venture capital firm with offices in Shanghai, San Francisco and Cambridge. Peter also serves as Chairman of FORMA Therapeutics (Nasdaq: FMTX), a clinical-stage biopharmaceutical company developing novel therapeutics for patients with rare hematologic diseases and cancers, as Chairman of Syros Pharmaceuticals (Nasdaq: SYRS), a biotechnology company redefining the power of small molecules to control the expression of genes, and as a Director of Zai Lab (Nasdaq: ZLAB), a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world.

From 1996 until its acquisition by Sanofi in 2011, Peter was a senior executive at Genzyme, most recently serving as Executive Vice President, Legal and Corporate Development, Chief Risk Officer and Corporate Secretary. During his time at Genzyme, Wirth had senior management responsibility for the company’s legal and corporate development functions, molecular oncology division, polymer drug discovery and development division and enterprise risk management function. He was instrumental in helping build Genzyme from a small start-up to a diversified, multi-billion dollar enterprise with more than 12,000 employees in locations spanning the globe.

Prior to joining Genzyme, Peter practiced law at Palmer & Dodge LLP, where he was head of the firm’s biotechnology practice group and served as outside general counsel for Genzyme as well as numerous other biopharmaceutical companies.

Peter received his B.A. from the University of Wisconsin-Madison and his J.D. from Harvard Law School.

Areas of Expertise: Corporate financing (including venture capital and capital structures), corporate governance (including recruiting and managing a Board of Directors and executive compensation planning) and corporate transactions (including corporate partnering and M&A).


termeer logo bottom